Analytical Data
-
基因名
CDK5-p25
- Application
-
别名
Cell division protein kinase 5Serine/threonine-protein kinase PSSALRETau protein kinase II catalytic subunit ;TPKII catalytic subunit
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q00535
-
表达区间
1-292aa
-
分子量
49.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK5 (Cyclin-Dependent Kinase 5) is a kinase that plays a critical role in neuronal development and function. Unlike other cyclin-dependent kinases, CDK5 is uniquely activated by its regulatory subunits, p35 and p25. The p25 fragment is derived from the cleavage of p35 by proteolytic enzymes, particularly during neuronal stress, and its accumulation is associated with various neurodegenerative diseases, including Alzheimer's disease. In contrast to p35, the p25 form of CDK5 leads to aberrant kinase activity, which has been implicated in the hyperphosphorylation of tau protein—a hallmark of neurodegenerative processes. Research involving the recombinant expression of CDK5-p25 fusion proteins allows for the detailed study of its enzymatic properties, substrate interactions, and downstream signaling pathways. Moreover, understanding the structural and functional distinctions between CDK5 complexes formed with p35 and p25 could provide insights into therapeutic targets for the prevention and treatment of tauopathies and dementia. Given the increasing prevalence of neurodegenerative disorders worldwide, elucidating the regulation of CDK5-p25 is a significant area of research, with potential implications for developing interventions aimed at restoring normal kinase function in affected neuronal populations.
